drugset / Trial / NCT03233308
Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the effect on trabecular outflow facility of Netarsudil ophthalmic solution 0.02% compared to placebo
Timeline
- Start
- 2017-10-20
- Primary completion
- 2018-04-19
- Completion
- 2018-04-19
Outcome
Met primary endpoint
registry analysis (other test); Netarsudil Ophthalmic Solution 0.02%; p = 0.0010; t-test, 1 sided NCT03233308 ↗
registry analysis (other test); Netarsudil Ophthalmic Solution 0.02%; p = 0.0003; t-test, 1 sided NCT03233308 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Netarsudil | Small molecule | 0.02 % | — |